A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy
Public ClinicalTrials.gov record NCT00035516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to learn if BMS-247550 can shrink or slow the growth of the cancer in patients with non-small cell lung cancer who have failed first-line platinum based chemotherapy. The safety of this treatment will also be studied.
Study identification
- NCT ID
- NCT00035516
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2001
- Primary completion
- Mar 31, 2004
- Completion
- Mar 31, 2004
- Last update posted
- Feb 9, 2016
2001 – 2004
United States locations
- U.S. sites
- 16
- U.S. states
- 14
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Un of California Davis Cancer Center | Sacramento | California | 958177 | — |
| Mount Sinai Medical Center | Miami Beach | Florida | 33140 | — |
| H Lee Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Rush Presbyterian St Lukes ME | Chicago | Illinois | 60612-3828 | — |
| Consultants in Blood Disorders | Louisville | Kentucky | 40207 | — |
| Ochsner Cancer Institute | New Orleans | Louisiana | 70121 | — |
| University of Maryland Greenbaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Lahey Clinic | Burlington | Massachusetts | 01805 | — |
| University of Missouri/Ellis Fischel Cancer Center | Columbia | Missouri | 65203 | — |
| Dartmouth-Hitchcock /Norris Cotton Cancer Center | Lebanon | New Hampshire | 03756 | — |
| Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| Unviversity of North Carolina | Chapel Hill | North Carolina | 27599 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Vanderbilt University Med School Div of Medical Oncology | Nashville | Tennessee | 37232-5536 | — |
| University of Wisconsin Hospital | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00035516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 9, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00035516 live on ClinicalTrials.gov.